Login Register
icon_bulk_orderBulk order Acrobiosystems for English
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Insights > [Newly Launched] Three anti-IFN γ antibodies in ACRO’s “mAb Matrix”
[Newly Launched] Three anti-IFN γ antibodies in ACRO’s “mAb Matrix”
Release time: 2022-05-06 Source: ACROBiosystems Read: 118

mAb Matrix

As a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics, vaccines, and diagnostics, ACROBiosystems has established an antibody product line named "mAb matrix". There are diverse antibodies in mAb matrix including biological target antibodies, biomarker antibodies, receptor antibodies, cytokine antibodies (interleukin antibodies, chemokine antibodies), virus antibodies, small molecular inhibitors antibodies, diagnostic antibodies, process engineering antibodies, etc. The "antibody matrix" series products are characterized with high specific and high sensitivity, and they are suitable for the methodology construction of both diagnosis and the entire process in the biopharmaceutical R&D, helping to accelerate the medicine R&D and commercial process.

antibody matrix

The functions of IFN-γ

The evolution of the immune system follows two basic rules: "destroy foreign objects when in danger, "Don't seriously harm the host". It is a difficult task to selectively treat normal cells and avoid immune lesions. Therefore, inflammation stimulates the regulation mechanism and starts tissue repair to restore physiological functions and internal stability. Interferon plays a core role between immune cells and non -immune cells.

IFN-γ is the only member of the type II interferon family and is a soluble cytokine. From a biological perspective, IFN-γ is a multi-effect cytokine with antiviral, antitumor and immune regulation. Therefore, IFN-γ plays an important role in coordinating congenital and adaptive immune reactions.

The interaction of IFN-γ with immune cells

The interaction of IFN-γ with immune cells

In an inflammatory environment, IFN-γ triggers the activation of an immune response that stimulates the clearance of pathogens, and it also prevents overactivation of the immune system and tissue damage, although the complex mechanisms that maintain this balance are not fully understood. In the tumor microenvironment (TME), IFN-γ always plays a coordinated anti-tumor and pro-tumor immune function. IFN-γ, together with granzyme B and perforin, act as cytotoxic cytokines to initiate tumor cell apoptosis. IFN-γ can also synthesize immune checkpoint inhibitory molecules and indoleamine 2,3-dioxygenase (IDO), thereby stimulating other immune suppression. Thus, although IFN-γ is a key factor in antitumor immunity, it can initiate an alternative program in tumor cells, providing tumor cells with additional capacity to respond to immune responses.

Pro-tumor and anti-tumor effects of IFN-γ

Pro-tumor and anti-tumor effects of IFN-γ

The structure of IFN-γ

IFN-γ is a protein encoded by the IFNG gene, consisting of two antiparallel polypeptide chains. Fully synthetic IFN-γ is glycosylated at the amino terminus and the level of glycosylation determines the final weight of the defined moiety. It has been reported that glycosylation itself does not affect the activity of interferon, but prevents its degradation by proteases. Thus, this chemical modification increases the half-life of IFN-γ in blood, prolonging its mediated effects.

ACROBiosystems developed recombinant IFN-γ proteins (Cat. No. IFG-H4211) expressed by HEK293 to achieve the post-translational glycosylation modification and correct protein folding; the high biological activity is verified by binding its receptor IFN-γ R1 and cell-based experiments. Click the form below to view more information and verification data of IFN-γ and IFN-γ R1 proteins.

Product list:IFN-γ and IFN-γ R1

MoleculeCat. No.SpeciesProduct Description
IFN-γIFG-H4211HumanActiveMax® Human IFN-gamma / IFNG Protein, Tag Free
IFN-γ R1IF1-H5223HumanHuman IFN-gamma R1 /IFNGR1 Protein, His Tag
IFN-γ R1IF1-H5254HumanHuman IFNGR1 / CD119 Protein, With C-Fc Tag

The detection of IFN-γ

FN-γ-mediated host-pathogen interactions are critical for studying disease mechanisms and also exhibit enormous therapeutic importance for the elimination of various infections and autoimmune diseases. T cells capable of recognizing and eliminating cancer cells were identified based on IFN-γ positivity during CAR-T cell therapy. In addition, selection of effector T cell clones is generally based on their IFN-γ production capacity. However, the expression of IFN-γ and the efficiency of CAR-T cell therapy in vivo are not always positively correlated, which suggesting an alternative role for IFN-γ in cancer immunoediting. Nonetheless, IFN-γ is still considered to be one of the most valuable parameters for predicting clinical response.

The production of IFN-γ and granulocyte-macrophage colony-stimulating factor (GM-CSF) by CAR-T cells can enhance antigen presentation, cell adhesion, and recruitment of Th1 cells, thereby enhancing host antitumor immunity. In addition, in order to improve the success rate of CAR-T cell therapy or prevent tumor recurrence, tumor-infiltrating macrophages need to be regulated by IFN-γ.

CAR-T cells target tumor cells and induce the release of cytokines such as IFN-γ

CAR-T cells target tumor cells and induce the release of cytokines such as IFN-γ

Cytokine release syndrome (CRS) and macrophage activation syndrome (MAS) are serious immunopathological consequences of adoptive T cell therapy including CAR-T. IFN-γ is thought to be a common player in these syndromes. In addition to increased levels of IFN-γ, mediators such as IL-6, IL-10, IFN-γ-induced chemokines, and TNF-α also contribute to potentially lethal toxicity and other adverse effects. Especially when chronically exposed to IFN-γ, macrophages differentiate into hemophagocytic cells and exacerbate the disease, suggesting that MAS has an IFN-γ-dependent physiopathology.

Therefore, the detection and monitoring of IFN-γ is particularly important in clinical practice.

At present, the detection of IFN-γ is usually carried out by the method of antigen-antibody specific binding. ACROBiosystems has launched three human-mouse chimeric anti-IFN γ antibodies derived from different clones: they can specifically bind to Human IFN-γ; they have been verified to be suitable for the detection of IFN-γ by antibodies sandwich method.

Product List
MoleculeCat. No.SpeciesProduct Description
Anti-IFNγ antibodyIFN-M411HumanMonoclonal Anti-IFNγ antibody, Human IgG1 (13E6H4)
IFN-M412HumanMonoclonal Anti-IFNγ antibody, Human IgG1 (8C5F8)
IFN-M414HumanMonoclonal Anti-IFNγ antibody, Human IgG1 (13E6H6)
Product Features

High purity: greater than 95% as verified by SDS-PAGE

High specificity: only specifically binds to IFN-γ, not to other cytokines (IL-2, IL-4, IL-6, IL-10, GM-CSF, TNF-alpha)

High biological activity: the binding activity and affinity to IFN-γ are verified by ELISA, SPR and BLI

High sensitivity: suitable for the detection of IFN-γ and the development of detection methods, the sensitivity can reach pg grade

Verification Data
Monoclonal Anti-IFNγ antibody, Human IgG1 (13E6H4),(Cat. No. IFN-M411)

Monoclonal Anti-IFNγ antibody, Human IgG1 (13E6H4) on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.

IFN-M411

Immobilized ActiveMax® Human IFN-gamma, Tag Free (Cat. No. IFG-H4211) can bind Monoclonal Anti-IFNγ antibody, Human IgG1 (13E6H4) (Cat. No. IFN-M411) with a linear range of 0.09-1.56 ng/mL (QC tested). No cross-reactivity is detected with other human cytokines, including IL-2, IL-4, IL-6, IL-10, GM-CSF and TNF-alpha.

IFN-M411

Monoclonal Anti-IFNγ antibody, Human IgG1 (Cat. No. IFN-M411) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind ActiveMax® Human IFN-gamma, Tag Free (Cat. No. IFG-H4211) with an affinity constant of 0.158 nM as determined in a SPR assay (Biacore 8K).

IFN-M411

Loaded Monoclonal Anti-IFNγ antibody, Human IgG1 (Cat. No. IFN-M411) on AHC Biosensor, can bind ActiveMax® Human IFN-gamma, Tag Free (Cat. No. IFG-H4211) with an affinity constant of 0.653 nM as determined in BLI assay (ForteBio Octet Red96e).

IFN-M411
Monoclonal Anti-IFNγ antibody, Human IgG1 (8C5F8),(Cat. No. IFN-M412)

Monoclonal Anti-IFNγ antibody, Human IgG1 (8C5F8) on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.

IFN-M412

Immobilized ActiveMax® Human IFN-gamma, Tag Free (Cat. No. IFG-H4211) can bind Monoclonal Anti-IFNγ antibody, Human IgG1 (8C5F8) (Cat. No. IFN-M412) with a linear range of 0.09-1.56 ng/mL (QC tested). No cross-reactivity is detected with other human cytokines, including IL-2, IL-4, IL-6, IL-10, GM-CSF and TNF-alpha.

IFN-M412

Monoclonal Anti-IFNγ antibody, Human IgG1 (8C5F8) (Cat. No. IFN-M412) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind ActiveMax® Human IFN-gamma, Tag Free (Cat. No. IFG-H4211) with an affinity constant of 41.1 pM as determined in a SPR assay (Biacore 8K).

IFN-M412

Loaded Monoclonal Anti-IFNγ antibody, Human IgG1 (Cat. No. IFN-M412) on AHC Biosensor, can bind ActiveMax® Human IFN-gamma, Tag Free (Cat. No. IFG-H4211) with an affinity constant of 0.545 nM as determined in BLI assay (ForteBio Octet Red96e)

IFN-M412
Monoclonal Anti-IFNγ antibody, Human IgG1 (13E6H6),(Cat. No. IFN-M414)

Monoclonal Anti-IFNγ antibody, Human IgG1 (13E6H6) on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.

IFN-M414

Immobilized ActiveMax® Human IFN-gamma, Tag Free (Cat. No. IFG-H4211) can bind Monoclonal Anti-IFNγ antibody, Human IgG1 (13E6H6) (Cat. No. IFN-M414) with a linear range of 0.07-0.63 ng/mL (QC tested). No cross-reactivity is detected with other human cytokines, including IL-2, IL-4, IL-6, IL-10, GM-CSF and TNF-alpha.

IFN-M414

Monoclonal Anti-IFNγ antibody, Human IgG1 (13E6H6) (Cat. No. IFN-M414) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind ActiveMax® Human IFN-gamma, Tag Free (Cat. No. IFG-H4211) with an affinity constant of 0.11 nM as determined in a SPR assay (Biacore 8K).

IFN-M414

Loaded Monoclonal Anti-IFNγ antibody, Human IgG1 (Cat. No. IFN-M414) on AHC Biosensor, can bind ActiveMax® Human IFN-gamma, Tag Free (Cat. No. IFG-H4211) with an affinity constant of 0.718 nM as determined in BLI assay (ForteBio Octet Red96e).

IFN-M414

We will launch other members of ACRO "Antibody Matrix" in succession. If you have any needs or more development suggestions, don't hesitate to contact us.

Leave a message

References:

1. M. Alper Kursunel, Gunes Esendagli. The untold story of IFN-γ in cancer biology, Cytokine & Growth Factor Reviews (2016). https://doi.org/10.1016/j.cytogfr.2016.07.005.

2. Jorgovanovic, D., Song, M., Wang, L. et al. Roles of IFN-γ in tumor progression and regression: a review. Biomarker Research (2020). https://doi.org/10.1186/s40364-020-00228-x

3. Maria Cosenza, Stefano Sacchi, Samantha Pozzi. Cytokine Release Syndrome Associated with T-Cell-Based Therapies for Hematological Malignancies: Pathophysiology, Clinical Presentation, and Treatment. J. Mol. Sci. (2021). https://doi.org/10.3390/ijms22147652

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message